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Introduction: Patients with very dilated left ventricle are less responder to
CRT. We evaluate implant process and per-operative impact of adding a
second LV lead in this population.
Methods: We consider 15 patients with CRT-D indication and EDLVD
70 mm.
Additional time for 2nd LV lead was limited to 40 minutes. Per-operative
impact was evaluated using an external hemodynamic sensor influenced by
cardiac contractility (PEA sensor). LV 1 is the postero-lateral one, the LV2 is
the high lateral or diagonal one. All patients with successful implantation were
discharged in Triv pacing mode.
We evaluate the best configuration (regarding contractility) for each LV
lead (BIV or LV only pacing mode). Comparing both configurations we
define the optimal lead, and the non-optimal one.
We compare these two configurations with the best configuration using the
two left ventricular lead (Triv pacing or dual left pacing) called the “optimal
dual left configuration”.
Results: 13 pts were successfully implanted with 2 LV leads (mean addi-
tional time=25 mins. [9-40]).
For 7 cases the optimal left lead is the postero-lateral one, for 6 it was the
high lateral or diagonal.
The “Optimal dual left configuration” upgrades the hemodynamic value
for more than 40% (41% [–2; 115]) compared with the non optimal lead,
and up to 10% (12% [–9,39; 41,82]) compared with the optimal one. 7/13 patients
have more than 10% of increase compared with optimal LV lead and the
positive impact of using the two LV lead is confirmed (TRIV vs Optimal
>0, p<0,05).
Choosing the optimal lead versus the non optimal one (40%) is statistically
superior than using the optimal dual left configuration versus the optimal lead
only (10%) (sign test p=0.0005).
Conclusions: In patients with dilated left ventricle, adding a second LV
lead ensures having the benefit of the best positioned left lead, and dual left
configuration adds an additional acute benefit over standard CRT.
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Guidelines recommend the electrophysiological evaluation of preexcitation
syndrome (PS) and report the indications of accessory pathway (AP) ablation
and the use of antiarrhythmic drugs for the treatment of supraventricular
tachycardias (SVT). PS-related adverse presentation defined as a documented
life-threatening haemodynamically not tolerated arrhythmia, should disappear.
The purpose of the study was to evaluate the prevalence of adverse events in
patients with known PS and their cause.
Methods: Adverse presentation occurred in 65 patients between 1990 and
2010 among 735 patients aged from 5 to 85 years (34.5±17), consecutively
recruited for a PS. Electrophysiological study (EPS) was systematic.
Results: The prevalence of adverse event was 8.5%. It was the first event
of the disease in 36 patients who had never ECG recording nor symptoms
before malignant arrhythmia (group I); 21 patients had symptoms of tachy-
cardia but no ECG was recorded and PS was unknown (group II). PS was
known but was not studied in 8 patients (group III): adverse event occurred
after heavy surgery (n=3), after use of calcium inhibitors (n=4) to treat spon-
taneous SVT and use of salbutamol (n=1). At EPS all group I and II patients
but 3, had the criteria of a malignant form of PS (maximal rate through
AP>240 bpm in control state, >300 bpm after isoproterenol in AF). In group
III, only 5 of 8 had the electrophysiological criteria of malignancy. Malignant
form at EPS was less frequent in group III than in group I and II (p<0.003).
Conclusions: EPS which should be systematic, because malignant form
was generally noted in asymptomatic or symptomatic patients with a PS who
presented a poorly-tolerated arrhythmia or a ventricular fibrillation. However
the risk can be underestimated in patients who will have a heavy surgery.
More, the management of PS remains to be improved, because some adverse
events are related to classically contraindicated drugs as calcium inhibitor
used to treat SVT.
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Introduction: Transvenous ventricular pacing (VP) has been traditionally
performed from the right ventricular apex (RVA) because convenience of
pacing electrode positioning and long-term pacing stability. Recently, the
adverse effects of pacing RVA have emerged. An increase in cumulative per-
centage of RVA pacing in patients treated with pacemakers results in
increased risk of heart failure hospitalization, and atrial fibrillation (AF).
To decrease the adverse consequences of RVA pacing, currently two strat-
egies are proposed: 1) substitute other VP sites, (right ventricular septum or
left ventricle), 2) use dual-chamber pacemakers with new function: Manage
Ventricular Pacing (MVP™) which operates in AAI/R mode with backup VP
during AV block (AVB).
Insertion level of the CS ostium (CSO)
